FDA Approves New Drug to Treat HIV Infection
The US Food and Drug Administration today approved Tivicay ( dolutegravir ), a new drug to treat HIV-1 infection.
Rapid Diagnostic Test to Detect Both HIV-1 Antigen and HIV-1/2 Antibodies
The US Food and Drug Administration today approved the first rapid human immunodeficiency virus (HIV) test for the simultaneous detection of HIV-1 p24 antigen as well as antibodies to both HIV-1 and HIV-2 in human serum, plasma, and venous or fingerstick whole blood specimens.
WHO Recommends Earlier Treatment of HIV
The AIDS epidemic is becoming more and more contained as doctors, researchers and organizations band together to study and fight this seemingly unstoppable virus. Fortunately, things are starting to look up.
Everyday Is a Good Day for HIV Testing
If you want to play a role in preventing the spread of HIV/AIDS, there are two great ways to do so. First, get tested. Next, get involved in this year's National HIV Testing Day.
Knowing the Options: HIV/AIDS Testing
The only way to get treatment for HIV and/or AIDS is to know that you have it. The first step to finding out if you have HIV is getting tested. So how does testing work?
Growing Up with HIV
Medical advances have changed the future of today's patients with HIV. Most children with HIV grow into adults these days. But that presents challenges, too.
HIV meets Hep C
Many people infected with HIV or hepatitis C aren’t aware of their infections. These unknown infections can strike especially hard in underserved and poor communities.
The Dream of an HIV Vaccine
Imagine a world where HIV/AIDS is no longer a major health concern – and not because of a cure for the disease but due to prevention of the disease before it even strikes. That is the dream for many researchers and health workers focused on fighting HIV.
Widening the Net for HIV Tests
Many people only consider getting an HIV screening after they think there has been a risk of exposure. Times may be changing. A few health officials are saying that this way of thinking should change.
NIH Discontinues Immunizations in HIV Vaccine Study
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will stop administering injections in its HVTN 505 clinical trial of an investigational HIV vaccine regimen because an independent data and safety monitoring board (DSMB) found during a scheduled interim review that the vaccine regimen did not prevent HIV infection nor reduce viral load (the amount of HIV in the blood) among vaccine recipients who became infected with HIV.